Editorial update on emerging drugs for cancer cachexia

Expert Opinion on Emerging Drugs

Volumn 17, Issue 1, 2012, Pages 5-9

  Murphy, Kate T ^a   Lynch, Gordon S ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

anorexia; cachexia; cancer; skeletal muscle; tumor; wasting

Indexed keywords

ACE 031; ALD 518; AMG 745; ANABOLIC AGENT; ANAMORELIN; ANTIBODY; APD 209; APPETITE STIMULANT; AVR 118; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BL 6020; BL 979; BYM 338; CARNITINE; CELECOXIB; FORMOTEROL; GTX 024; ICOSAPENTAENOIC ACID; INTERLEUKIN 6 ANTIBODY; LENALIDOMIDE; LGD 4033; MACIMORELIN; MEGESTROL ACETATE; MT 102; OSTARINE; PF 354; SELECTIVE ANDROGEN RECEPTOR MODULATOR; SNT 207707; SNT 209858; THALIDOMIDE; UNCLASSIFIED DRUG;

ADVANCED CANCER; CACHEXIA; CANCER CACHEXIA; CATABOLISM; DRUG EFFICACY; HUMAN; MUSCLE ATROPHY; NONHUMAN; PATHOGENESIS; REVIEW; TREATMENT OUTCOME; WEAKNESS;

ANABOLIC AGENTS; APPETITE STIMULANTS; CACHEXIA; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; HUMANS; INTERLEUKIN-6; NEOPLASMS; QUALITY OF LIFE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84858966221     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.2012.652946     Document Type: Review

References (20)

1. Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 2011;12:489-95 A Delphi process was applied to develop international consensus for the definition and classification of cancer cachexia.
2. Fouladiun M, Korner U, Bosaeus I, et al. Body composition and time course changes in regional distribution of fat and lean tissue in unselected cancer patients on palliative care - correlations with food intake, metabolism, exercise capacity, and hormones. Cancer 2005;103:2189-98 (Pubitemid 40605128)
3. Baracos VE, Reiman T, Mourtzakis M, et al. Body composition in patients with non-small cell lung cancer: a contemporary view of cancer cachexia with the use of computed tomography image analysis. Am J Clin Nutr 2010;91:1133S-7S
4. Murphy KT, Lynch GS. Update on emerging drugs for cancer cachexia. Expert Opin Emerg Drugs 2009;14:619-32 This review serves the basis of the present Editorial and should be consulted (along with the present Editorial) for a comprehensive evaluation of the emerging drugs for cancer cachexia.
5. Dallmann R, Weyermann P, Anklin C, et al. The orally active melanocortin-4 receptor antagonist BL-6020/979: a promising candidate for the treatment of cancer cachexia. J Cachex Sarcopenia Muscle 2011;2:163-74
6. Mantovani G. Randomised phase III clinical trial of 5 different arms of treatment on 332 patients with cancer cachexia. Eur Rev Med Pharmacol Sci 2010;14:292-301 A comprehensive study with clearly defined endpoints comparing the efficacy of five different arms of treatment for patients with cancer cachexia, which should be used as a template for future combination studies.
7. Davis M, Lasheen W, Walsh D, et al. A phase II dose titration study of thalidomide for cancer-associated anorexia. J Pain Symptom Manage 2011; In Press
8. Wilkes EA, Selby AL, Cole AT, et al. Poor tolerability of thalidomide in end-stage oesophageal cancer. Eur J Cancer Care (Engl) 2011;20:593-600
9. Rigas JR, Schuster M, Orlov SV, et al. Effect of ALD518, a humanized anti-IL-6 antibody, on lean body mass loss and symptoms in patients with advanced non-small cell lung cancer (NSCLC): Results of a phase II randomized, double-blind safety and efficacy trial. J Clin Oncol 2010;28(Suppl): abstract 7622
10. Chasen M, Hirschman SZ, Bhargava R. Phase II study of the novel peptide-nucleic acid OHR118 in the management of cancer-related anorexia/cachexia. J Am Med Dir Assoc 2011;12:62-7
11. Mantovani G, Maccio A, Madeddu C, et al. Phase II nonrandomized study of the efficacy and safety of COX-2 inhibitor celecoxib on patients with cancer cachexia. J Mol Med (Berl) 2010;88:85-92
12. Morton RAJ, Barnette KG, Hancock ML, et al. The use of a selective androgen receptor modulator to improve lean body mass and muscle performance in patients with cancer cachexia. Endocrine Society Annual Meeting; Washington; 2009. p. S21-1
13. Murphy KT, Chee A, Gleeson BG, et al. Antibody-directed myostatin inhibition enhances muscle mass and function in tumor-bearing mice. Am J Physiol 2011;301:R716-R26
14. Zhou X, Wang JL, Lu J, et al. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell 2010;142:531-43 Reported reversal of cachexia and prolonged survival with administration of an activin type IIB receptor decoy to tumor-bearing mice.
15. Murphy RA, Yeung E, Mazurak VC, et al. Influence of eicosapentaenoic acid supplementation on lean body mass in cancer cachexia. Br J Cancer 2011;105:1469-73 An excellent review of recent trials investigating the efficacy of EPA supplementation for treating cancer cachexia.
16. Penna F, Busquets S, Pin F, et al. Combined approach to counteract experimental cancer cachexia: eicosapentaenoic acid and training exercise. J Cachex Sarcopenia Muscle 2011;2:95-104
17. Lenk K, Schuler G, Adams V. Skeletal muscle wasting in cachexia and sarcopenia: molecular pathophysiology and impact of exercise training. J Cachexia Sarcopenia Muscle 2010;1:9-21
18. Busquets S, Figueras MT, Fuster G, et al. Anticachectic effects of formoterol: a drug for potential treatment of muscle wasting. Cancer Res 2004;64:6725-31 (Pubitemid 39297935)
19. von Haehling S, Stepney R, Anker SD. Advances in understanding and treating cardiac cachexia: highlights from the 5th Cachexia Conference. Int J Cardiol 2010;144:347-9
20. Stewart Coats AJ, Srinivasan V, Surendran J, et al. The ACT-ONE trial, a multicentre, randomised, double-blind, placebo-controlled, dose-finding study of the anabolic/catabolic transforming agent, MT-102 in subjects with cachexia related to stage III and IV non-small cell lung cancer and colorectal cancer: study design. J Cachex Sarcopenia Muscle 2011;2:201-7